Algeta ASA : Proposal from the Nomination Committee to the Annual General Meeting on 11 April 2013
(Thomson Reuters ONE) -
To the Shareholders of Algeta ASA
Reference is made to the announcement of 19 March 2013 regarding Algeta ASA's
Annual General Meeting 2013 and agenda item 13: Election of members to the Board
of Directors. At the time of the announcement, the Nomination Committee had not
decided on its proposal for new members of the Board of Directors. The
Nomination Committee has now made its decision - please find the proposal
attached.
###
For further information, please contact:
Mike Booth / Renate Birkeli +47 23 00 67 32
Communications & Corporate Affairs ir(at)algeta.com
Media enquiries:
Mark Swallow +44 207 638 9571
Citigate Dewe Rogerson mark.swallow(at)citigatedr.co.uk
Knut Ekern +47 22 04 82 00
Gambit Hill & Knowlton knut.ekern(at)hkstrategies.com
US investor enquiries:
Tricia Swanson +1 646 378 2953
The Trout Group tswanson(at)troutgroup.com
About Algeta
Algeta is a company focused on developing novel targeted therapies for patients
with cancer based on its alpha-pharmaceutical platform. The Company is
headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in
Cambridge, MA performing commercial marketing operations in the US. Algeta is
listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please
visit www.algeta.com.
Forward-looking Statements
This news release contains certain forward-looking statements that are based on
uncertainty, as they relate to events and depend on circumstances that will
occur in the future and which, by their nature, may have an impact on results of
operations and the financial condition of Algeta. Such forward-looking
statements reflect our current views and are based on the information currently
available to Algeta. Algeta cannot give any assurance as to whether such forward
looking statements will prove to be correct. These forward looking statements
include statements regarding interactions with regulatory authorities, our
anticipated co-promotion of radium-223 in the US, additional clinical
development of radium-223 and our TTC program. There are a number of factors
that could cause actual results and developments to differ materially from those
expressed or implied by these forward-looking statements. These factors include,
among other things, risks or uncertainties associated with the success of future
clinical trials, collaborations with other companies in the development of
targeting molecules, the ability to identify and hire a sufficient number of
qualified employees for the US field force, growth management, general economic
and business conditions and the pricing environment, the impact of competition,
the ability to successfully commercialize radium-223 and our other products, the
risk that costs associated with the co-promotion of radium-223 may be greater
than anticipated, the risk that research & development will not yield new
products that achieve commercial success, manufacturing capacity, the risk of
non-approval of patents not yet granted, risks in obtaining regulatory approvals
for radium-223 and our other products and difficulties of obtaining relevant
governmental approvals for new products, and the other risks and uncertainties
described in our annual report.
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Proposal from the Nomination Committee to the AGM 2013:
http://hugin.info/134655/R/1690509/554984.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
[HUG#1690509]
Unternehmensinformation / Kurzprofil:
Datum: 05.04.2013 - 08:45 Uhr
Sprache: Deutsch
News-ID 246274
Anzahl Zeichen: 4839
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 118 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta ASA : Proposal from the Nomination Committee to the Annual General Meeting on 11 April 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
